Assignee
NuCana plc
GB·29 granted patents·22 pending applications·114 citations·filing 2004–2025
Top patents by PatentIndex Score
51 records- 0196US11559542B2Phosphoramidate derivatives of 5-fluoro-2′-deoxyuridine for use in the treatment of cancerNuCana plc·Filed 2021·Granted Jan 24, 2023·3 cites·19 claims
- 0295US11040051B2Formulation comprising a gemcitabine-prodrugNuCana plc·Filed 2020·Granted Jun 22, 2021·4 cites·20 claims
- 0395US10117888B2Formulation comprising a gemcitabine-prodrugNuCana plc·Filed 2015·Granted Nov 6, 2018·23 cites·29 claims
- 0494US10786523B2Formulation comprising a gemcitabine-prodrugNuCana plc·Filed 2018·Granted Sep 29, 2020·8 cites·24 claims
- 0594US10022390B2Phosphoramidate derivatives of 5-fluoro-2′-deoxyuridine for use in the treatment of cancerNuCana plc·Filed 2017·Granted Jul 17, 2018·13 cites·20 claims
- 0690USRE47589EPhosphoramidate compounds and methods of useNuCana plc·Filed 2004·Granted Sep 3, 2019·34 cites·25 claims
- 0788US11352387B22′ and/or 5′ amino-acid ester phosphoramidate 3′-deoxy adenosine derivatives as anti-cancer compoundsNuCana plc·Filed 2020·Granted Jun 7, 2022·2 cites·19 claims
- 0888US10993957B2Phosphoramidate derivatives of 5-fluoro-2′-deoxyuridine for use in the treatment of cancerNuCana plc·Filed 2018·Granted May 4, 2021·4 cites·25 claims
- 0988US10570168B22′ and/or 5′ amino-acid ester phosphoramidate 3′-deoxy adenosine derivatives as anti- cancer compoundsNuCana plc·Filed 2015·Granted Feb 25, 2020·5 cites·4 claims
- 1086US10774104B2Diastereoselective synthesis of phosphate derivativesNuCana plc·Filed 2016·Granted Sep 15, 2020·4 cites·26 claims
- 1185US12357652B2Formulations of phosphoramidate derivatives of nucleoside drugsNuCana plc·Filed 2023·Granted Jul 15, 2025·0 cites·20 claims
- 1285US11925658B2Phosphoramidate derivatives of 5-fluoro-2′—deoxyuridine for use in the treatment of cancerNuCana plc·Filed 2023·Granted Mar 12, 2024·0 cites·10 claims
- 1385US10660912B2Combination therapy for cancerNuCana plc·Filed 2015·Granted May 26, 2020·4 cites·15 claims
- 1484US2025171487A1Synthesis of phosphate derivativesNuCana plc·Filed 2024·Application pending·0 cites
- 1582US10906929B2Phosphoramidate nucleoside derivatives as anticancer agentsNuCana plc·Filed 2017·Granted Feb 2, 2021·2 cites·16 claims
- 1681US10669300B2Methods of separating gemcitabine-phosphate diastereoisomersNuCana plc·Filed 2015·Granted Jun 2, 2020·2 cites·20 claims
- 1780US11414452B2Synthesis of phosphate derivativesNuCana plc·Filed 2018·Granted Aug 16, 2022·1 cites·7 claims
- 1880US10662213B2Gemcitabine prodrugsNuCana plc·Filed 2015·Granted May 26, 2020·3 cites·13 claims
- 1980US2025302859A1Formulations of phosphoramidate derivatives of nucleoside drugsNuCana plc·Filed 2025·Application pending·0 cites
- 2079US12054511B2Synthesis of phosphate derivativesNuCana plc·Filed 2022·Granted Aug 6, 2024·0 cites·26 claims
- 2178US2024293439A1Treatment regimensNuCana plc·Filed 2023·Application pending·0 cites
- 2276US2023226092A1Cancer treatments based on gemcitabine prodrugsNuCana plc·Filed 2022·Application pending·0 cites
- 2375US12054510B22′ and/or 5′ amino-acid ester phosphoramidate 3′-deoxy adenosine derivatives as anti-cancer compoundsNuCana plc·Filed 2022·Granted Aug 6, 2024·0 cites·8 claims
- 2475US11707477B2Formulation comprising a gemcitabine-prodrugNuCana plc·Filed 2021·Granted Jul 25, 2023·0 cites·11 claims
- 2575US11414451B2Floxuridine synthesisNuCana plc·Filed 2018·Granted Aug 16, 2022·1 cites·32 claims
- 2674US11786544B2Formulations of phosphoramidate derivatives of nucleoside drugsNuCana plc·Filed 2021·Granted Oct 17, 2023·0 cites·9 claims
- 2773US2022323475A1Combination therapy for cancerNuCana plc·Filed 2022·Application pending·0 cites
- 2871US2023192750A1Salts of diphosphate phosphoramidate of nucleosides as anticancer compoundsNuCana plc·Filed 2022·Application pending·0 cites
- 2970US11400107B2Cancer treatmentsNuCana plc·Filed 2017·Granted Aug 2, 2022·1 cites·16 claims
- 3070US2025144128A1Cancer treatmentNuCana plc·Filed 2024·Application pending·0 cites
- 3169US2023149436A1Combination therapyNuCana plc·Filed 2022·Application pending·0 cites
- 3265US11897913B2Synthesis of 3′-deoxyadenosine-5′-O-[phenyl(benzyloxy-L-alaninyl)]phosphate (NUC-738)NuCana plc·Filed 2018·Granted Feb 13, 2024·0 cites·8 claims
- 3365US11603382B2Diastereoselective synthesis of phosphate derivativesNuCana plc·Filed 2020·Granted Mar 14, 2023·0 cites·23 claims
- 3465US2023218655A1Cancer treatmentsNuCana plc·Filed 2022·Application pending·0 cites
- 3564US11040997B2Process for preparing nucleoside prodrugsNuCana plc·Filed 2018·Granted Jun 22, 2021·0 cites·8 claims
- 3664US2021100825A1Cancer treatments based on gemcitabine prodrugsNuCana plc·Filed 2020·Application pending·0 cites
- 3764US2020268783A1Combination therapy for cancerNuCana plc·Filed 2020·Application pending·0 cites
- 3863US2025163096A12' and/or 5' amino-acid ester phosphoramidate 3'-deoxy adenosine derivatives as anti-cancer compoundsNuCana plc·Filed 2024·Application pending·0 cites
- 3963US2021130387A1Phosphoramidate nucleoside derivatives as anticancer agentsNuCana plc·Filed 2021·Application pending·0 cites
- 4062US11629164B2Gemcitabine prodrugsNuCana plc·Filed 2020·Granted Apr 18, 2023·0 cites·10 claims
- 4162US2020345755A1Treatment RegimensNuCana plc·Filed 2018·Application pending·0 cites
- 4262US2022033433A1Process for preparing nucleoside prodrugsNuCana plc·Filed 2021·Application pending·0 cites
- 4360US2025296948A1Synthesis of nucleoside derivativesNuCana plc·Filed 2025·Application pending·0 cites
- 4455US2019022117A1Combination therapyNuCana plc·Filed 2016·Application pending·0 cites
- 4555US2018289733A1Cancer treatments based on gemcitabine prodrugsNuCana plc·Filed 2015·Application pending·0 cites
- 4655US2022024963A1Salt of triphosphate phosphoramidates of nucleotides as anticancer compoundsNuCana plc·Filed 2021·Application pending·0 cites
- 4755US2018369266A1Formulations of phosphoramidate derivatives of nucleoside drugsNuCana plc·Filed 2016·Application pending·0 cites
- 4852US11377467B2Crystalline form of gemcitabineNuCana plc·Filed 2016·Granted Jul 5, 2022·0 cites·5 claims
- 4951US11560400B2Salts of diphosphate phosphoramidate of nucleosides as anticancer compoundsNuCana plc·Filed 2018·Granted Jan 24, 2023·0 cites·27 claims
- 5049US2020197430A1Combination TherapyNuCana plc·Filed 2018·Application pending·0 cites
Showing the top 50 of 51 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →